Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 2/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.31 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | CHRNG | P07510 | 1/20 | 0.31 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
| ▸ | CHRND | Q07001 | 1/20 | 0.31 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5198549 | 0.79 | PDGFRB (0.50) | — | |
| Hydrochloric Acid SCHEMBL11071908 | 0.78 | PDGFRB (0.49) | — | |
| Hydrochloric Acid SCHEMBL10819124 | 0.78 | PDGFRB (0.49) | — | |
| Methyl Alcohol SCHEMBL10773137 | 0.75 | PDGFRB (0.50) | — | |
| SCHEMBL10771544 | 0.74 | NR4A2 (0.45) | — | |
| SCHEMBL11985803 | 0.71 | GAA (0.41) | — | |
| SCHEMBL30997837 | 0.71 | CYP1A2 (0.43) | — | |
| SCHEMBL12532560 | 0.71 | CHRNB4 (0.37) | CHRNB4CHRNA3CHRNA1ESR1CHRNG | |
| SCHEMBL1612114 | 0.71 | CHRNB4 (0.40) | CHRNB4CHRNA3CHRNA1ESR1CHRNG | |
| SCHEMBL1712774 | 0.70 | GPR84 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200163877-A1 | LIPOSOME FORMULATIONS | OPKO PHARMACEUTICALS, LLC. | 2020-05-28 | — | — | US | claimed |
| US-20190321467-A1 | LIPOSOME FORMULATIONS | OPKO PHARMACEUTICALS, LLC. | 2019-10-24 | — | — | US | claimed |
| US-20150224055-A1 | LIPOSOME FORMULATIONS | OPKO PHARMACEUTICALS, LLC | 2015-08-13 | — | — | US | claimed |
| US-11712419-B2 | Liposome formulations | OPKO PHARMACEUTICALS, LLC (US) | 2023-08-01 | — | — | US | disclosed |
| US-11458199-B2 | Liposome formulations | OPKO PHARMACEUTICALS, LLC (US) | 2022-10-04 | — | — | US | disclosed |
| EP-2887958-B1 | LIPOSOME FORMULATIONS | OPKO PHARMACEUTICALS LLC (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20200163877-A1 | LIPOSOME FORMULATIONS | OPKO PHARMACEUTICALS, LLC. | 2020-05-28 | — | — | US | disclosed |
| US-10548841-B2 | Liposome formulations | OPKO PHARMACEUTICALS, LLC (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190321467-A1 | LIPOSOME FORMULATIONS | OPKO PHARMACEUTICALS, LLC. | 2019-10-24 | — | — | US | disclosed |
| EP-3165606-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL DISEASES | Ophthotech Corporation (US) | 2017-05-10 | — | — | EP | disclosed |
| US-20160264969-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL DISEASES | OPHTHOTECH CORPORATION | 2016-09-15 | — | — | US | disclosed |
| EP-0779889-A4 | PYRAZOLO 3,4-g]QUINOXALINE COMPOUNDS WHICH INHIBIT PDGF RECEPTOR PROTEIN TYROSINE KINASE | RHONE POULENC RORER PHARMA (US) | 2000-02-23 | — | — | EP | disclosed |
| EP-0779889-A4 | PYRAZOLO 3,4-g]QUINOXALINE COMPOUNDS WHICH INHIBIT PDGF RECEPTOR PROTEIN TYROSINE KINASE | RHONE POULENC RORER PHARMA (US) | 2000-02-23 | — | — | EP | disclosed |
| EP-0779889-A1 | PYRAZOLO 3,4-g]QUINOXALINE COMPOUNDS WHICH INHIBIT PDGF RECEPTOR PROTEIN TYROSINE KINASE | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1997-06-25 | — | — | EP | disclosed |
| EP-0779889-A1 | PYRAZOLO 3,4-g]QUINOXALINE COMPOUNDS WHICH INHIBIT PDGF RECEPTOR PROTEIN TYROSINE KINASE | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1997-06-25 | — | — | EP | disclosed |
| WO-1996007658-A1 | PYRAZOLO[3,4-g]QUINOXALINE COMPOUNDS WHICH INHIBIT PDGF RECEPTOR PROTEIN TYROSINE KINASE | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-03-14 | — | — | WO | disclosed |
| WO-1996007658-A1 | PYRAZOLO[3,4-g]QUINOXALINE COMPOUNDS WHICH INHIBIT PDGF RECEPTOR PROTEIN TYROSINE KINASE | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-03-14 | — | — | WO | disclosed |
| US-5476851-A | Administering as therapeutic agents for various disease states which are characterized by uncontrolled cellular proliferation | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1995-12-19 | — | — | US | disclosed |
| US-5476851-A | Administering as therapeutic agents for various disease states which are characterized by uncontrolled cellular proliferation | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1995-12-19 | — | — | US | disclosed |
| US-5476851-A | Administering as therapeutic agents for various disease states which are characterized by uncontrolled cellular proliferation | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1995-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264969-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL DISEASES | VEGFA, PDGFA, PGF | CHRNB4 2877/4885CHRNA3 1649/4885CHRNA1 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.